KSC · 326030.KS
SK Biopharmaceuticals Co., Ltd.
₩77,200-₩600 (-0.77%)
SK Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 46.43% below the high.
Loading market information…
KOE · 347850.KQ · KRW
Stock price
Quote as of Oct 30, 2026, 03:38 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
D&D Pharmatech’s quoted price sits in the lower half of its reported 52-week range, 65.91% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:59 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩77,200-₩600 (-0.77%)
SK Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 46.43% below the high.
₩93,400-₩3,800 (-3.91%)
Peptron, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.2% below the high.
₩106,000-₩9,200 (-7.99%)
Voronoi, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.77% below the high.
₩6,670-₩270 (-3.89%)
GI Innovation, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.16% below the high.
₩2,495-₩65 (-2.54%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.02% below the high.
₩6,970-₩510 (-6.82%)
FutureChem Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 75.08% below the high.
₩3,660+₩40 (+1.1%)
Helixmith Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 63.25% below the high.
₩2,910-₩60 (-2.02%)
MedPacto, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.36% below the high.
